Join our LinkedIn PATENTSCOPE users Community Group
تعليقات
الإعدادات

الإعدادات

الانتقال إلى التطبيق

32,194 نتيجة
المكاتب all اللغات تجذير false عضو أسرة براءات فريدة true إدراج مجموعة الوثائق خلاف البراءات false
لا يمكن توليد موجز RSS إلا إذا كان لديك حساب لدى الويبو

حفظ الاستعلام

يكون الاستعلام الخاص مرئيا لك وحدك عند تسجيل دخولك ولا يمكن استخدامه في مواجز RSS

شجرة الاستعلام

تحسين الخيارات

المكاتب
الكل
الرجاء تحديد لغة الكلمات الرئيسية المستعملة في البحث
التجدير يرجع الكلمات المُصرفة إلى جذرها أو أصلها الإشتقاقي.
فمثلا، أعيدت الكلمات fishing وfished وfish وfisher إلى أصل الكلمة الإشتقاقي، fish، بحيث يحيل أي بحث يدور حول المصطلح fisher إلى جميع الصيغ المختلفة.
يرجع عضو واحد من عائلة براءات الاختراع
إدراج مجموعة الوثائق خلاف البراءات في النتائج

استعلام كامل

IC:G01N33/569

عرض مفاتيح الاختصار جنبا إلى جنب

عام
اذهب إلى إدخال البحث
CTRL + SHIFT +
اذهب إلى النتائج (التدوين المختار)
CTRL + SHIFT +
اذهب إلى التفصيل (علامة التبويب المختارة)
CTRL + SHIFT +
اذهب إلى الصفحة التالية
CTRL +
اذهب إلى الصفحة السابقة
CTRL +
النتائج (اختر أولا "اذهب إلى النتائج")
اذهب إلى التدوين التالي/ الصورة التالية
/
اذهب إلى التدوين السابق/ الصورة السابقة
/
انتقل صعوداً
Page Up
انتقل نزولاً
Page Down
انتقل إلى أعلى الصفحة
CTRL + Home
انتقل إلى أسفل الصفحة
CTRL + End
التفصيل (اختر أولا "اذهب إلى التفصيل")
اذهب إلى علامة التبويب التالية
اذهب إلى علامة التبويب السابقة

تحليل

1 / 3,220
1.WO/2024/097313METHODS FOR PRODUCING T CELL THERAPY PRODUCTS
WO - 10.05.2024
التصنيف الدولي A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 رقم الطلب PCT/US2023/036627 مودع الطلب SANA BIOTECHNOLOGY, INC. المخترع JOHNSON, Adam James
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g., as CAR T cell therapy). Methods are also provided of profiling the donor capability of a cell or population of cells for cell therapy, such methods comprising evaluating the cell or the population of cells for predicted function. A predicted cell function may be evaluated by assaying one or more cell parameters. Further, cells and cell therapy products manufactured according to such methods are provided.
2.WO/2024/098072IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OF CANCER AND MYELOID-MEDIATED DISEASES
WO - 10.05.2024
التصنيف الدولي G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 رقم الطلب PCT/US2023/078854 مودع الطلب THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES المخترع KRATZMEIER, Sabina, A.
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
3.WO/2024/097730SENSOR STABILITY
WO - 10.05.2024
التصنيف الدولي G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 رقم الطلب PCT/US2023/078317 مودع الطلب GLUCOVATION, INC. المخترع SURI, Jeffrey
Sensor stability is crucial to successful, long term in situ analyte measurement. Systems, methods and devices herein exhibit increased long term measurement accuracy of circulating analytes, such as glucose, lactose, or others, which makes the technology herein particularly suitable for real time, long term in situ analyte measurement. Systems, methods and devices herein variously comprise crosslinked sensor layers, sensor sites that are internal to rather than at an edge of an insulating layer and other structural improvements, as well as sensors exhibiting the improved long-term stability in analyte measurement resulting therefrom or otherwise facilitating long term use.
4.WO/2024/097314METHODS AND SYSTEMS FOR DETERMINING DONOR CELL FEATURES AND FORMULATING CELL THERAPY PRODUCTS BASED ON CELL FEATURES
WO - 10.05.2024
التصنيف الدولي G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
 رقم الطلب PCT/US2023/036628 مودع الطلب SANA BIOTECHNOLOGY, INC. المخترع JOHNSON, Adam James
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g., as CAR T cell therapy). Methods are also provided of profiling the donor capability of a cell or population of cells for cell therapy, such methods comprising evaluating the cell or the population of cells for predicted function. A predicted cell function may be evaluated by assaying one or more cell parameters. Further, cells and cell therapy products manufactured according to such methods are provided.
5.WO/2024/097315CELL THERAPY PRODUCTS AND METHODS FOR PRODUCING SAME
WO - 10.05.2024
التصنيف الدولي A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 رقم الطلب PCT/US2023/036629 مودع الطلب SANA BIOTECHNOLOGY, INC. المخترع JOHNSON, Adam James
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g.. as CAR T cell therapy). Methods are also provided of profiling the donor capability of a cell or population of cells for cell therapy, such methods comprising evaluating the cell or the population of cells for predicted function. A predicted cell function may be evaluated by assaying one or more cell parameters. Further, cells and cell therapy products manufactured according to such methods are provided.
6.WO/2024/095174PROGNOSTIC BIOMARKERS FOR CANCER RELAPSE VACCINATION AND THE USE THEREOF
WO - 10.05.2024
التصنيف الدولي G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 رقم الطلب PCT/IB2023/061000 مودع الطلب MENDUS B.V. المخترع ROVERS, Jeroen
Disclosed provides a method of treating measure residue disease (MRD) in a subject with cancer using an allogeneic leukemia-derived cell as a vaccine based on the information provided by prognostic biomarkers comprising dendritic cells including cDC1 cDC2, and/or pDC; CD8+ T cells including CD8+CD45RA+ cells, CD8+ CD45RA- CCR7+ CM T cells, and/or CD8 RO+ T cells; B cells; NK cells including CD56++ NK cells and/or CD56+ NK cells; CD4 CD161+ T cells; CD14+CD16- non-inflammatory monocytes, or any combination thereof.
7.WO/2024/097725A METHOD FOR DETERMINING THE INFECTIVITY OF A VIRUS
WO - 10.05.2024
التصنيف الدولي G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 رقم الطلب PCT/US2023/078311 مودع الطلب TAKEDA VACCINES, INC. المخترع LIVENGOOD, Jill
The present invention relates to a method for determining the infectivity of a virus, in particular a flavivirus. Further, a method for determining the titer of a virus-specific antibody in a sample is provided. In addition, the use of the method in the quality control of vaccines and in the diagnosis of an infection are provided as well. The present invention also provides a method for determining the proportion of infectious virus particles in a sample comprising infectious and non-infectious virus particles. The present invention further relates to a maturation assay for determining the average maturation degree. The present invention also relates to novel anti-dengue virus serotype 2 (DENV2) and anti-dengue virus serotype 4 (DENV4) antibodies and antigen binding fragments thereof being useful in the method of the invention. Further, nucleic acids encoding them and host cells comprising them are provided. In addition, the use of the antibodies in the prevention or treatment of dengue disease is provided. Also, diagnostic methods using them and kits comprising them are provided.
8.20240150836METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS
US - 09.05.2024
التصنيف الدولي C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 رقم الطلب 18504868 مودع الطلب THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM المخترع Jason Y. Park

The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of transcripts, autoantibody levels, cytokine levels, and immune cells. The irAE can be ICI-related myositis, ICI-related myocarditis or ICI-related myositis and myocarditis.

9.20240148850N PROTEIN EPITOPE MUTATION MARKER FOR PREPARING EPITOPE DELETION-MARKED VACCINE STRAIN OF TYPE II PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND USE THEREOF
US - 09.05.2024
التصنيف الدولي A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 رقم الطلب 17997749 مودع الطلب Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences المخترع Jing ZHANG

The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

10.20240151720PROCESS FOR SELECTING CELL CLONES EXPRESSING A HETEROLOGOUS POLYPEPTIDE
US - 09.05.2024
التصنيف الدولي G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 رقم الطلب 18377668 مودع الطلب Hoffmann-La Roche Inc. المخترع Tobias Grosskopf

Herein is reported a novel, high throughput suitable method for the characterization and identification as well as selection of recombinant cell clones expressing a bispecific antibody with high titers and low levels of antibody-related side products. The method according to the current invention uses the binding signals of an immunoassay-based screening of recombinant cell clone cultivation supernatants for isolated as well as simultaneous binding to the respective targets of the antibody. This data allows for the selection of high producer cell clones with desired product profile.

# -